Two years ago, Pfizer announced it had partnered with biotech company Celldex to develop a brain cancer vaccine. At the time, many people thought the move heralded the beginning of pharmaceutical companies developing personalized treatments for patients, says Robert Langreth on Forbes' Treatments blog. But now Pfizer has dissolved the partnership, leaving Celldex to try and develop the drug on its own.